Financial News

Financial Report: Roche

Pharmaceutical sales up 6% in the quarter

By: Kristin Brooks

Managing Editor, Contract Pharma

Roche
2Q Revenues: $28.3 billion (+7%)
2Q Earnings: $7.6 billion (+35%)
Comments: Pharmaceutical sales were $22.0 billion in the quarter, up 6% driven mainly by Ocrevus, used to treat two forms of multiple sclerosis, and cancer medicines Perjeta, Alecensa and Tecentriq. Ocrevus sales were up 456% to $1.0 billion in the quarter. Perjeta sales were up 23% to $1.3 billion. Tamiflu contributed with high sales at the beginning of the year due to a severe flu season.

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters